Gynecologic Cancer InterGroup (GCIG) shared a post on LinkedIn:
“In two weeks, GCIG convenes in Toronto for the 7th Ovarian Cancer Consensus Conference (OCCC), and the timing could not be more significant.
Since the 6th OCCC in 2021, the ovarian cancer treatment landscape has shifted considerably. New data. New therapies. New questions about how clinical trials should be designed to reflect them.
The 7th OCCC brings together leading researchers and clinicians from across GCIG’s 33 cooperative group members for two intensive days of presentation, debate, breakout discussion, and voting on consensus statements that will shape the next generation of ovarian cancer trials.
This year’s conference, chaired by Amit Oza (Princess Margaret Cancer Centre) and Jung-Yun Lee (KGOG), will embed four cross-cutting themes throughout every session:
- Translational Integration
- Global Access
- Patient Centricity
- Equity and Diversity
The meeting culminates in a manuscript development session immediately following closing remarks, with the goal of translating consensus into published guidance for the research community.
We look forward to welcoming delegates to Toronto on 30 April.”
To which Kristina Lindemann, Head of the Gynecological Oncology Center at Oslo University Hospital, added:
“Looking forward to shaping the future of clinical research in ovarian cancer with colleagues from all over the world.
Very honored to take part on behalf of NSGO-CTU.
See you in Toronto!”
Other articles featuring GCIG and Kristina Lindemann on OncoDaily.